Skip to content

MaxCyte MXCT Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Repligen logo
RepligenRGEN
-$5.59M-15.7%
BioSig Technologies, Inc. logo
BioSig Technologies, Inc.STEX

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's short- and long-term operating lease liabilities?
MaxCyte (MXCT) reported short- and long-term operating lease liabilities of -$456K in Q1 2026.
How has MaxCyte's short- and long-term operating lease liabilities changed year-over-year?
MaxCyte's short- and long-term operating lease liabilities decreased by 64.0% year-over-year, from -$278K to -$456K.
What is the long-term trend for MaxCyte's short- and long-term operating lease liabilities?
Over 3 years (2021 to 2025), MaxCyte's short- and long-term operating lease liabilities has grown at a -33.2% compound annual growth rate (CAGR), from $3.87M to -$1.16M.